Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: The role of survivin

Oncotarget

Volumn 6, Issue 15, 2015, Pages 1-14

  De Cesare, Michelandrea ^a   Cominetti, Denis ^a   Doldi, Valentina ^a   Lopergolo, Alessia ^a   Deraco, Marcello ^a   Gandellini, Paolo ^a   Friedlander, Sharon ^b   Landesman, Yosef ^b   Kauffman, Michael G ^b   Shacham, Sharon ^b   Pennati, Marzia ^a   Zaffaroni, Nadia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Karyopharm Therapeutics Inc   (United States)

Author keywords

Diffuse malignant peritoneal mesothelioma; SINE; Survivin; XPO1 CRM1

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; EXPORTIN 1; KPT 251; KPT 276; NUCLEAR PROTEIN; PROTEASOME; PROTEIN P53; SELINEXOR; SEPANTRONIUM BROMIDE; SURVIVIN; UNCLASSIFIED DRUG; ACRYLAMIDE DERIVATIVE; BIRC5 PROTEIN, HUMAN; CDKN1A PROTEIN, MOUSE; CELL RECEPTOR; EXPORTIN 1 PROTEIN; HYDRAZINE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; KARYOPHERIN; KPT-251; KPT-276; KPT-330; OXADIAZOLE DERIVATIVE; THIAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE; TUMOR PROTEIN; CASPASE 11; CASPASE 3; CASPASE 7; SELECTIVE INHIBITORS OF NUCLEAR EXPORT; UBIQUITIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL GROWTH; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DISEASE MODEL; DRUG EFFICACY; DRUG POTENTIATION; G1 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PERITONEUM MESOTHELIOMA; PROTEIN DEGRADATION; PROTEIN FUNCTION; TREATMENT DURATION; TUMOR XENOGRAFT; UBIQUITINATION; ACTIVE TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; PATHOLOGY; PERITONEAL NEOPLASMS; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL LINE; ADULT; BIOACCUMULATION; CANCER INHIBITION; CELL LEVEL; DIFFUSE MALIGNANT PERITONEUM MESOTHELIOMA; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG MECHANISM; DRUG SCREENING; EARLY CANCER; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; NUCLEAR EXPORT SIGNAL; PRECLINICAL STUDY; PROTEIN LOCALIZATION; TOXICITY TESTING;

ACRYLAMIDES; ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; HYDRAZINES; INHIBITOR OF APOPTOSIS PROTEINS; KARYOPHERINS; LUNG NEOPLASMS; MESOTHELIOMA; MICE; MICE, SCID; NEOPLASM PROTEINS; OXADIAZOLES; PERITONEAL NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; TRIAZOLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84979895730     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3761     Document Type: Article

References (46)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005; 353:1591-1603.
2. Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013; 20:1093-1100.
3. Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. Diffuse malignant peritoneal mesothelioma-an update on treatment. Cancer Treat Rev. 2012; 38:605-612.
4. Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013; 49:3140-3148.
5. Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M. Diffuse malignant peritoneal Mesothelioma: failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2009; 16:463-472.
6. Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M, Erdas R, Cabras A, Kusamura S, Baratti D, Deraco M, Daidone MG. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothe-lioma. Cell Oncol. 2007; 29:453-466.
7. Altieri DC. Targeting survivin in cancer. Cancer Lett. 2013; 332:225-228.
8. Stauber RH, Mann W, Knauer SK. Nuclear and Cytoplasmic Survivin: Molecular Mechanism, Prognostic, and Therapeutic Potential. Cancer Res. 2007; 67:5999-6002.
9. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol. 2012; 83:1021-1032.
10. Rodriguez JA, Span SW, Ferreira CGM, Kruyt FEA, Giaccone G. Crm1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein survivin. Experimental Cell Research. 2002; 275:44-53.
11. Nguyen KT, Holloway MP, Altura RA. The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol. 2012; 3:137-151.
12. Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, Zhang L, Ou Z, Li C, Sun L, Ford RJ, Pham LV. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol. 2013; 41:67-78.
13. Azmi AS, Aboukameel A, Bao B, Sarkar FH, Philip PA, Kauffman M, Shacham S, Mohammad RM. Selective inhib-itors of nuclear export block pancreatic cancer cell prolif-eration and reduce tumor growth in mice. Gastroenterology. 2013; 144:447-456.
14. Sun Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, Macmillan J, Chook YM. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci USA. 2013; 110:1303-1308.
15. Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, Sanda T, Mansour MR, Barcelo C, McCauley D, Kauffman M, Shacham S, Christie AL, Kung AL, et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia. 2013; 27:66-74.
16. Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood. 2012; 120:4621-4634.
17. Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M, Croce CM, Marcucci G, Garzon R. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012; 120:1765-1773.
18. Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Kantarjian H, et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013; 121:4166-4174.
19. Inoue H, Kauffman M, Shacham S, Landesman Y, Yang J, Evans CP, Weiss RH. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol. 2013; 189:2317-2326.
20. Salas Fragomeni RA, Chung HW, Landesman Y, Senapedis W, Saint-Martin JR, Tsao H, Flaherty KT, Shacham S, Kauffman M, Cusack JC. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Mol Cancer Ther. 2013; 12:1171-1179.
21. Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P. Blood. 2013; 122:3034-3044.
22. Cheng Y, Holloway MP, Nguyen K, McCauley D, Landesman Y, Kauffman MG, Shacham S, Altura RA. XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer. Mol Cancer Ther. 2014; 13:675-686.
23. Mendonca J, Sharma A, Kim HS, Hammers H, Meeker A, De Marzo A, Carducci M, Kauffman M, Shacham S, Kachhap S. Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer. Oncotarget. 2014; 5:6102-6112.
24. Sun H, Hattori N, Chien W, Sun Q, Sudo M, E-Ling GL, Ding L, Lim SL, Shacham S, Kauffman M, Nakamaki T, Koeffler HP. KPT-330 has antitumour activity against non-small cell lung cancer. Br J Cancer. 2014; 111:281-291.
25. Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi AA, Senapedis W, Saint-Martin JR, Kashyap T, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014; 28:155-165.
26. Yang J, Bill MA, Young GS, La Perle K, Landesman Y, Shacham S, Kauffman M, Senapedis W, Kashyap T, Saint-Martin JR, Kendra K, Lesinski GB. Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells. PLoS One. 2014; 9:e102983.
27. Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quintás-Cardama A, McDonnell TJ, Neelapu SS, Kwak LW, Shacham S, Kauffman M, Tabe Y, Yokoo M, Kimura S, et al. Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci. 2014; 105:795-801.
28. Zheng Y, Gery S, Sun H, Shacham S, Kauffman M, Koeffler HP. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma. Cancer Chemother Pharmacol. 2014; 74:487-495.
29. Zhong Y, El-Gamal D, Dubovsky JA, Beckwith KA, Harrington BK, Williams KE, Goettl VM, Jha S, Mo X, Jones JA, Flynn JM, Maddocks KJ, Andritsos LA, et al. Selinexor suppresses downstream effectors of B-cell acti-vation, proliferation and migration in chronic lymphocytic leukemia cells. Leukemia. 2014; 28:1158-1163.
30. Chan KS, Wong CH, Huang YF, Li HY. Survivin with-drawal by nuclear export failure as a physiological switch to commit cells to apoptosis. Cell Death Dis. 2010; 1:e57.
31. Hung MC, Link W. Protein localization in disease and therapy. J Cell Sci. 2011; 124:3381-3392.
32. Gerecitano J. SINE (selective inhibitor of nuclear export)-translational science in a new class of anti-cancer agents. J Hematol Oncol. 2014; 7:67.
33. Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B, Yoshida M, Horinouchi S. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA. 1999; 96:9112-9117.
34. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer. 1996; 74:648-649.
35. Noske A, Weichert W, Niesporek S, Röske A, Buckendahl AC, Koch I, Sehouli J, Dietel M, Denkert C. Expression of the nucler export protein chromosomal region maintenance/exportin 1/Xpol is a prognostic factor in hum-man ovarian cancer. Cancer. 2008; 112:1733-1743.
36. Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH, Sun YJ. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med. 2009; 32:E315.
37. Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery. 2009; 65:153-159.
38. van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, Birrer MJ, Leaner VD. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for can-cer cell survival and proliferation. Int J Cancer. 2009; 124:1829-1840.
39. Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Chen P, Sun YJ, Tang LN, Zheng SE. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep. 2009; 21:229-235.
40. Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Kantarjian H, et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013; 121:4166-4174.
41. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408:307-310.
42. Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, Wahl GM. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 1999; 18:1660-1672.
43. Shaulsky G, Goldfinger N, Ben-Ze'ev A, Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol. 1990; 10:6565-6577.
44. Parikh K, Cang S, Sekhri A. Selective inhibitors of nuclear export (SINE)-a novel class of anti-cancer agents. J Hematol Oncol. 2014; 7:78.
45. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55.
46. Kern DH, Morgan CR, Hildebrand-Zanki SU. In vitro pharmacodynamics of 1-b-d-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloro-platinum (II). Cancer Res. 1988; 48:117-121.